749929-04-2

Usage

Uses

Used in Organic Synthesis:
1-(4-bromo-2-fluorophenyl)cyclobutanecarbonitrile is used as a building block for the synthesis of various organic compounds. Its unique structure and functional groups allow for the creation of new molecules with specific properties, making it a valuable asset in the field of organic chemistry.
Used in Medicinal Chemistry:
In the pharmaceutical industry, 1-(4-bromo-2-fluorophenyl)cyclobutanecarbonitrile is used as a key intermediate in the development of new drugs. Its structural diversity and functional groups enable the design and synthesis of novel therapeutic agents with improved efficacy and selectivity.
Used in Material Science:
1-(4-bromo-2-fluorophenyl)cyclobutanecarbonitrile is also utilized in material science for the development of advanced materials with specific properties. Its unique structure and functional groups can be exploited to create materials with tailored characteristics, such as improved mechanical strength, thermal stability, or chemical resistance.

Upstream product

• 114897-91-5 (4-bromo-2-fluorophenyl)acetonitrile 
• 109-64-8 1,3-dibromo-propane 

Downstream Products

• 1314788-41-4 1-(4-bromo-2-fluorophenyl)cyclobutanecarboxylic acid 
• 1314668-55-7 1-(4-bromo-2-fluorophenyl)-cyclobutylamine 

Relevant academic research and scientific papers

SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS

The present invention provides novel heterocyclic compounds of the general formula (I), including novel compounds of formula (la), and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) or (la) and the pharmaceutical compo

Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same

The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1 and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula (I), and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).